Does Metformin Affect the Kidneys?
Metformin does not directly damage the kidneys, but it is renally excreted and accumulates when kidney function declines, increasing the risk of lactic acidosis—a rare but serious complication. The primary concern is not nephrotoxicity but rather safe use in the context of existing renal impairment.
Key Mechanism: Renal Excretion, Not Renal Toxicity
Metformin is substantially excreted unchanged by the kidneys, with clearance proportional to GFR 1, 2. The drug does not cause kidney damage itself; rather, reduced kidney function impairs metformin elimination, leading to drug accumulation. This accumulation can precipitate lactic acidosis by decreasing hepatic lactate uptake and increasing blood lactate levels 2.
Evidence-Based GFR Thresholds for Safe Use
The most recent FDA guidance (2016) and major guidelines provide clear eGFR-based recommendations 3, 4, 5:
Safe to Continue:
- eGFR ≥45 mL/min/1.73 m²: Continue metformin at standard doses 3, 5
- Monitor eGFR at least annually; increase to every 3-6 months when eGFR <60 4, 5
Dose Reduction Required:
- eGFR 30-44 mL/min/1.73 m²: Reduce dose to maximum 1000 mg daily 3, 4, 5
- eGFR 45-59 mL/min/1.73 m²: Consider dose reduction in patients with comorbidities increasing lactic acidosis risk (heart failure, liver disease, alcoholism, hypoxemia) 4
Contraindicated:
- eGFR <30 mL/min/1.73 m²: Stop metformin; do not initiate 3, 5, 2
- eGFR 30-45 mL/min/1.73 m²: Do not initiate new therapy 3, 2
Critical "Sick Day Rules" to Prevent Acute Kidney Injury
Temporarily discontinue metformin during acute illnesses that increase AKI risk 1:
- Acute intercurrent illness: Sepsis, hypoxia, dehydration, shock, acute heart failure
- Surgical procedures: When food/fluid intake is restricted 2
- Contrast imaging: Stop before iodinated contrast procedures in patients with eGFR 30-60 mL/min/1.73 m² or those with liver disease, alcoholism, or heart failure 6, 2
These situations create conditions where metformin clearance drops acutely while lactate production increases, creating a perfect storm for lactic acidosis.
Actual Risk of Lactic Acidosis: Lower Than Historically Feared
The absolute risk of metformin-associated lactic acidosis is exceedingly rare when used appropriately. A Cochrane meta-analysis of 347 studies found zero cases of lactic acidosis in 37,360 patient-years of metformin use, with no increased lactate levels compared to other antihyperglycemic agents 1. Even in patients with eGFR 30-60 mL/min/1.73 m², lactic acidosis remains rare despite comorbidities like heart failure and COPD 7.
However, when lactic acidosis does occur, it is characterized by:
- Blood lactate >5 mmol/L
- Anion gap acidosis
- Metformin plasma levels generally >5 mcg/mL 2
Management: Prompt hemodialysis (metformin is dialyzable with clearance up to 170 mL/min) 2
Mortality Benefit Despite Renal Impairment
Importantly, metformin use in patients with eGFR 30-60 mL/min/1.73 m² is associated with reduced 2-year mortality compared to other glucose-lowering therapies 1. In the Swedish National Diabetes Register (n=51,675), mortality risk was reduced in patients with eGFR 45-60 and remained equivalent (not increased) in those with eGFR 30-45 1.
Potential Renoprotective Effects
Emerging research suggests metformin may actually improve renal outcomes in diabetic nephropathy through multiple mechanisms 8, 9, 10:
- Activation of AMPK/PPARα pathways reducing lipotoxicity
- Reduction of renal inflammation and fibrosis
- Modulation of MAPK signaling and carbohydrate metabolism 11
Common Pitfalls to Avoid
Over-restriction based on outdated creatinine cutoffs: The old FDA black-box warning (SCr >1.5 mg/dL in men, >1.4 mg/dL in women) is obsolete—use eGFR instead 7, 3
Failure to implement sick-day rules: Most lactic acidosis cases occur during acute illness when metformin is not temporarily stopped 1, 6
Not monitoring eGFR regularly: Check at least annually, more frequently (every 3-6 months) when eGFR <60 4, 5
Forgetting vitamin B12 monitoring: Check B12 levels in patients on metformin >4 years 5, 2
Unnecessary discontinuation before contrast in low-risk patients: Only stop if eGFR 30-60 AND additional risk factors present 6, 2
Bottom Line Algorithm
For patients with normal/mildly reduced kidney function (eGFR ≥60):
- Continue metformin; monitor eGFR annually
For eGFR 45-59:
- Continue metformin; monitor eGFR every 3-6 months
- Consider dose reduction if high-risk comorbidities present
For eGFR 30-44:
- Reduce to maximum 1000 mg daily; monitor eGFR every 3-6 months
- Educate on sick-day rules
For eGFR <30:
- Stop metformin; contraindicated
During acute illness/procedures:
- Temporarily hold metformin until stable and eGFR reassessed